Business Context and Reporting Period
Company: Nektar Therapeutics
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2009
Business Overview: Nektar is a clinical-stage biopharmaceutical company developing drug candidates using PEGylation and advanced polymer conjugate technology platforms. The company operates in a single segment focusing on oncology, pain, anti-infectives, and immunology. Following the sale of its pulmonary assets to Novartis in December 2008, the company's results for 2009 are not comparable to the prior year.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2009 | Six Months Ended June 30, 2008 |
|---|---|---|
| Total Revenue | $22,699 | $40,393 |
| Net Loss | $(63,876) | $(74,080) |
| Net Loss Per Share (Basic & Diluted) | $(0.69) | $(0.80) |
| Operating Cash Flow | $(71,077) | $(96,425) |
| Cash, Cash Equivalents & Short-term Investments | $294,303 | $378,994 |
| Total Debt (Convertible Notes & Capital Leases) | $234,571 | $235,302 |
| Product Gross Margin % | 10% | 35% |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 44% year-over-year for the six-month period. This was primarily driven by a 73% drop in collaboration revenue due to the termination of the Tobramycin Inhalation Powder (TIP) agreement and the assignment of the Cipro Inhale agreement to Novartis. Product sales and royalties also declined 12% due to lower volumes.
- Expense Reductions: Research and Development (R&D) expenses decreased 32% and General and Administrative (G&A) expenses decreased 20%. These reductions resulted from the Novartis asset sale (transferring ~140 personnel and facilities) and workforce reductions executed in early 2008.
- Margin Compression: Product gross margin percentage fell from 35% to 10%. This was caused by a shift in product mix, decreased manufacturing volumes leading to unabsorbed overhead, and a $2.1 million success fee payment to a former consulting firm.
- Improved Net Loss: Despite lower revenue, the net loss improved by approximately $10.2 million compared to the prior year, largely due to significant reductions in operating expenses.
Guidance, Outlook, and Risks
- Outlook: Management expects to continue substantial investments in advancing its pipeline. Revenue is expected to decrease in 2009 due to the loss of Novartis-related revenue streams. However, a potential one-time license extension payment of $31.0 million is expected in December 2009 if a partner exercises an option.
- Liquidity: As of June 30, 2009, the company held approximately $294.3 million in cash and investments against $241.2 million in indebtedness. Management believes current resources are sufficient to meet cash needs for at least the next twelve months.
- Key Risks:
- Partnership Dependency: The company relies heavily on collaboration partners (e.g., Bayer, UCB, Roche) for funding, development, and commercialization. Failure to secure new partnerships for candidates like Oral NKTR-118 could materially harm the business.
- Debt Obligations: The company carries significant debt, including $215.0 million in convertible subordinated notes due in 2012. Inability to generate cash flow or raise capital could lead to liquidity issues.
- Development Uncertainty: Drug development is inherently risky; clinical failures or regulatory delays could negatively impact financial prospects.
Investor Verification Checklist
- Verify the status and potential terms of the collaboration partnership for Oral NKTR-118 following the positive Phase 2 results.
- Confirm the likelihood of the $31.0 million license extension payment expected in December 2009.
- Monitor the company's cash burn rate relative to its $294.3 million cash position to assess runway for operations.
- Review the progress of Phase 2 trials for NKTR-102 (PEGylated irinotecan) and Phase 1 trials for NKTR-105 (PEGylated docetaxel).
- Assess the impact of the $215.0 million convertible note maturity in 2012 on future capital raising strategies.